| Teva Pharmaceutical Industries Limited - SWOT | | | | market by completing the acquisition of Barr |
| Analysis company profile is the essential source for | | | | Pharmaceuticals, a US based multinational generic |
| top-level company data and information. Teva | | | | pharmaceutical company, for $7.5 billion in December |
| Pharmaceutical Industries Limited - SWOT Analysis | | | | 2008. The company conducts its global operations in |
| examines the company's key business structure and | | | | North America, Europe, Latin America, Asia and Israel. |
| operations, history and products, and provides | | | | Teva is headquartered in Petach Tikva, Israel and |
| summary analysis of its key revenue lines and | | | | employed 38,307 people as of December 2008. The |
| strategy. | | | | company recorded revenues of $11,085 million during |
| Teva Pharmaceutical Industries (Teva) is the world's | | | | the financial year (FY) ended December 2008, an |
| leading generic pharmaceutical company. It is engaged | | | | increase of 17.8% over FY2007. The operating profit |
| in the development, production and marketing of | | | | of the company was $1,145 million during FY2008, a |
| generic, proprietary branded pharmaceuticals and | | | | decrease of 52.2% over FY2007. The net profit was |
| active pharmaceutical ingredients. Teva further | | | | $635 million in FY2008, a decrease of 67.5% over |
| enhanced its leadership position in the US generic | | | | FY2007. |